Araştırma özeti
Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by
BackgroundPrevious genome-wide association studies investigating the relationship between the HLA-DRB1 and the risk of Parkinson's disease (PD) have shown limited racial diversity and have not explored clinical heterogeneity extensively.MethodsThe study consisted of three parts: a case-control study, a cross-sectional study, and a longitudinal cohort study. The case-control study included 477 PD patients and 477 healthy controls to explore the relationship between rs660895 and PD susceptibility. The cross-sectional study utilized baseline data from 429 PD patients to examine the correlation between rs660895 and PD features. The longitudinal study included 388 PD patients who completed a 3-year follow-up to investigate the effects of rs660895 on PD progression.ResultsIn the case-control study, HLA-DRB1 rs660895-G allele was associated with a decreased risk of PD in allele model (adjusted OR=0.72, p = 0.003) and dominant model (AG + GG vs. AA: adjusted OR = 0.67, p = 0.003). In the cross-sectional analysis, there was no association between rs660895 and the onset age, motor phenotype, or initial motor symptoms. In the longitudinal analysis, PD patients with the G allele exhibited a slower progression of motor symptoms (MDS-UPDRS-III total score: β = -5.42, p ptime × genotype β = -4.78, p = 0.030, interaction ptime × genotype ConclusionOur findings support HLA-DRB1 rs660895-G allele is a protective genetic factor for PD risk in Chinese population. Furthermore, we also provide new evidence for the protective effect of rs660895-G allele in PD progression.
Bilimsel değerlendirme
Araştırma sorusu
Sorunun kapsamı orijinal çalışma üzerinden değerlendirilir.
Yöntem ve örneklem
Çalışma tasarımı ve örneklem için kaynak makaleyi kontrol edin.
Temel bulgular
Bu kayıt için editoryal olarak onaylanmış bulgu özeti henüz yayımlanmadı.
Sınırlılıklar
Sonuçların genellenebilirliği, yanlılık ve klinik anlamı ayrıca incelenmelidir.
Bibliyografik veriden yöntem, örneklem veya klinik sonuç çıkarımı yapılmaz.